Pioneering diagnostics
E.g., 16/02/2019
E.g., 16/02/2019

bioMérieux – Business review for the nine months ended September 30, 2017

18 October, 2017

  • Solid growth in sales, up 10.7% at constant exchange rates and scope of consolidation
    • €1,674 million in sales
    • Up 10.8% as reported
  • In microbiology, growth accelerated to nearly 8%
  • Contribution from all regions to the Group's strong...

bioMérieux – First-Half 2017 Results

30 August, 2017

bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

31 July, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® MS, its MALDI-TOF1 Mass...

Sysmex and bioMérieux Agreed to Dissolve the Joint Venture Sysmex bioMérieux Co., Ltd.

27 July, 2017

Sysmex Corporation (“Sysmex”) and bioMérieux S.A. (“bioMérieux”) (Paris:BIM) announce they have agreed to transfer all of Sysmex’ holdings in Sysmex bioMérieux Co., Ltd. (Tokyo, Japan) to bioMérieux thereby dissolving the joint venture created by and between the...

Second-Quarter 2017 Business Review

20 July, 2017

  • Good sales dynamic confirmed in second-quarter 2017, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation:
    • €1,134 million in sales
    • Up 13.3% as reported
  • Noticeable...

boMérieux receives FDA Clearance for BioFire's FilmArray® Respiratory Panel 2 (RP2)

The FilmArray® RP2 reduces sample-to-result time to only 45 minutes while enhancing pathogen coverage and overall sensitivity

01 June, 2017

 

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its molecular biology affiliate, has received 510(k) clearance from the FDA for the FilmArray® Respiratory Panel 2 (RP2). The FilmArray®...

The FilmArray® Respiratory Panel 2 plus (RP2plus) gets CE marked

20 April, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that the FilmArray® Respiratory Panel 2...

bioMérieux – First-Quarter 2017 Business Review

20 April, 2017

  • Strong sales dynamic in first-quarter 2017, with sales up 13.7% at constant exchange rates and scope of consolidation:
    • €568 million in sales
    • Up 16.3% as reported...

bioMérieux receives FDA 510(k) clearance for its BacT/ALERT® VIRTUO™ fully automated blood culture system

05 April, 2017

bioMérieux, a major player in the field of in vitro diagnostics, and the world leader in microbiology, announces that BacT/ALERT® VIRTUO™, its fully automated blood culture system, has received 510(k) clearance from the U.S. Food and Drug...

bioMérieux – 2016 Financial Results

01 March, 2017

  • Remarkable growth in sales in 2016, up 9.6% at constant exchange rates and scope of consolidation:
    • €2,103 million in sales
    • Up 7.1% as reported...